Roche's GLP-1/GIP Agonist Enicepatide Shows 16% Weight Loss in Mid-Stage Trial
Roche announced positive results from a mid-stage trial of its experimental drug enicepatide, a dual GLP-1 and GIP receptor agonist. The once-weekly injectable led to approximately 16% weight loss over about 12 months among obese or overweight adults with type 2 diabetes. The findings highlight the potential for Roche's treatment in addressing obesity-related metabolic conditions, particularly as it targets two key hormones involved in appetite and glucose regulation. The results could position enicepatide competitively against other GLP-1 drugs currently on the market or in development. This trial outcome may influence investor sentiment toward pharmaceutical companies developing similar therapies for weight management and diabetes treatment.
Tickers: $RHHBY
Topics: GLP-1/GIP receptor agonist type 2 diabetes treatment weight loss drug development